ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 3Q2024 results that showed a much improved cash balance of $4.2 million due in large part to the grant described ...
Botanical drugs are considered relatively safe from generic competition because a generic is required to be bioequivalent to the approved botanical drug. This requirement is difficult for a third ...
For many, the high cost of treatment leads to poor adherence to prescription, thus worsening health outcomes. The introduction of bioequivalent OnArni by USV Pvt. Ltd. offers an affordable, timely ...
Study data show that the new formulation is bioequivalent to the Zofran immediate-release tablet (developed by Novartis), and in August 2017 it received marketing approval in Japan under the name ...
The Economic Impact of Generic Drugs and Biosimilars: Cutting Healthcare Costs Generic drugs are bioequivalent versions of brand-name medications, offering the same active ingredients, dosage ...
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine ...
The first CI used in transplantation, CsA, was approved by the US Food and Drug Administration in 1983. CsA was rapidly adopted into immunosuppressive regimens. The results of early pivotal ...
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tamiflu for Oral Suspension, 6 mg/mL, of Hoffmann-La Roche, Inc, it added. The approval by the US ...
Follow-up if symptoms of hyperammonemia occur. Suicidal tendencies (monitor). Depakote ER is not bioequivalent to delayed-release tabs on mg/mg basis. Avoid abrupt cessation. Monitor platelets ...